Search PubMed⌕ Search

Biomedical subjects

R Fujii

Publications and source records attributed to R Fujii.

At least 289 records · Page 16Linked to original sources
PubMed1980

[Clinical studies on cefoperazone in the pediatric field (author's transl)].

Cefoperazone (CPZ) at dose levels of 80 approximately 100 mg/kg/day, divided 3 approximately 4 times, was drip-infused or intravenously injected for a period of 2 approximately 6 days to 10 patients. All 10 cases, 4 cases of bronchopneumonia from which H. influenzae was detected (Group A S. pyogenes and S. pneumoniae were also detected in each 1 case). 2 cases of coli urinary tract infection, 1 case of acute colitis from which pathogenic E. coli was detected, 1 case of E. coli carrier, 1 case of acute bronchitis (bacteria were not detected), and 1 case of urinary tract infection (bacteria were not detected) showed rapid improvement of clinical symptoms with rapid eradication of the pathogenic bacteria. In one case of urinary tract infection where S. epidermidis and S. faecalis were simultaneously detected, S. epidermidis was removed but S. faecalis was merely decreased. The effective antibacterial concentration after intravenous injection of CPZ in the feces was determined and found to be present in sufficient concentrations to prevent colon infection. No particular side effects were observed during CPZ therapy.

Age Factors↗
PubMed1980

[Studies of the real state of antibiotic consumption at an university hospital. Study in the pediatric department (author's transl)].

Antibiotic use at the Department of Pediatrics, Teikyo University Hospital was studied from 1974 to 1978, during which period a marked change was observed in the antibiotic consumption of Japan on the whole. From the view point of net weight of antibiotics consumed, beta-lactam antibiotics have been increasing up to more than 90% of antibiotic consumption and then follow macrolides and aminoglycoside substances. Chloramphenicol which was once the top antibiotic prescribed, and tetracyclines which have not been our choice, both have become very minor antibiotics in our present prescription. More than 90% of oral antibiotics were prescribed for outpatients and more than 90% of injectable antibiotics were administered to outpatients. Concerning oral penicillins, major three were ACPC, ABPC and AMPC for these years and as to oral CEPs most of them was CEX. ABPC and the fixed combination of ABPC and penicillinase resistant penicillin, were the top choice among injectable penicillins and CEZ was the top among CEPs. Concerning aminoglycoside antibiotic SM and KM were preferred as antituberculosis drug, and GM and DKB as antipseudomonas drug which took the main role in place with CBPC and SBPC since 1976. The type of oral drug preferred by pediatricians for prescription was also investigated and dry syrup type was found to be the most important one for pediatrics use. In spite of a steady increase of our outpatients for these five years, there was observed a remarkable decrease in number of antibiotic prescriptions, namely from 8,223 in 1974 to 4,613 in 1978. The reason is esteemed due to our policy to restrict possibly the needless use of oral antibiotics.

Anti-Bacterial Agents↗
PubMed1979

[Results of a multicentric clinical study of mezlocillin in Japan (author's transl)].

In a clinical trial including 701 patients 6-((R)-2-[3-methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen) proved effective in the treatment of severe infections. It showed a particularly high efficacy in septicaemia and endocarditis and in purulent meningitis. In cases unresponsive to previous treatment with other antibiotics mezlocillin was effective in about two-thirds of the cases. Side effects were slight and of the same nature as those accompanying other penicillins.

Adolescent↗
PubMed1979

[Clinical evaluation of CS-1170 in pediatric field (author's transl)].

CS-1170 was used for treatment of 26 children who were diagnosed as bacterial infections, and a response rate of 88% was obtained as the drug was effective in 15 of 17 determinable cases. In our evaluation, daily dosage of 75 approximately 270 mg/kg (100 approximately 200 mg/kg in the majority of the cases) was divided into 4 doses, and administered intravenously by one-shot injection over a 10-minute period. The period of drug administration ranged from 1.5 to 25.5 days, but in most cases it was 3 to 6 days. Elevation of GOT and GPT as a side effect of the drug was seen in one case (3.8%), which was reverted to normal level upon cessation of the drug administration.

Acute Disease↗
PubMed1979

[Clinical studies of cefamandole in children (author's transl)].

Clinical studies on cefamandole were carried out with the following results. (1) Cefamandole was administered 100 mg/kg/day (q.i.d.) by intravenous route to 29 cases of children. In 10 out of 29 cases bacteriological effect was observed. Bacteriological response was effective in 8 cases (80.0%). Clinical responses were effective in 27 cases (93.1%). (2) As to adverse reactions, granulocytopenia and elevation of S-GOT, S-GPT developed in each two cases.

Agranulocytosis↗
PubMed1979

[Clinical experience with cefuroxime in pediatric field (author's transl)].

Cefuroxime (CXM) was administered to 11 patients with pediatric bacterial infections, and clinical effective results were obtained in all these cases. Causative organisms detected in 5 cases with respiratory tract infection, and with urinary tract infections were all eliminated, and the bacterial count decreased in patients with colitis. As for side effect, 1 case developed eosinophilia, and another case with impaired liver function as underlying disease showed transitory exacerbated examination values. Time-course determinations of blood levels and urinary excretions were performed in 1 case. Fecal levels were determined in 2 cases but could not be detected; inactivation action of CXM was observed from the same fecal filtrate.

Bacterial Infections↗
PubMed1978

New plasmid (pTU512), mediating resistance to penicillin, erythromycin, and kanamycin, from clinical isolates of Staphylococcus aureus.

Multiply drug-resistant strains of Staphylococcus aureus were isolated from pediatric patients with severe staphylococcal infections in 1974 through 1976. Resistance to benzylpenicillin, erythromycin, and kanamycin was jointly eliminated without exception from these multiply drug-resistant strains by treatment with ethidium bromide. It was also found that the triple drug resistance in a representative strain, TK512-200, was always transduced to a susceptible strain simultaneously. Moreover, a single class of plasmid deoxyribonucleic acid was isolated from a transductant and found to be 14.4 +/- 0.6 mum in length, with a molecular weight corresponding to 29.8 x 10(6). From these results, it is concluded that the plasmid (pTU512) is a new one, mediating resistance to penicillin, erythromycin, and kanamycin.

DNA, Circular↗
PubMed1977

Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan.

The Japan Research Committee of Fosfomycin was organized in the fall of 1972 to promote the basic and clinical studies on fosfomycin. First of all, a subcommittee of fosfomycin consisting of a limited number of members was organized to establish the methods of determination on its antibacterial activity and its concentration in the biological fluid, and the most applicable methods were devised. The clinical trials on its oral form in a small scale were commenced from spring in 1973, and then gradually expanded to almost all of Japan. The clinical trials on its parenteral intravenous form were also undertaken from the latter half of 1973. The basic and clinical results obtained from hospitals and institutes almost all over Japan, to which members of the above Committee belong, were presented by speakers under a hot discussion in two symposia which were held by the Japan Society of Chemotherapy; one on its oral form in June 1974, and another on its parenteral form in December 1974. I served as chairman in both of the symposia. The clinical results of fosfomycin in Japan which were mainly collected in both symposia are described below. Its antibacterial activity, and absorption and exretion will be presented elsewhere in this volume. Clinical results of its oral form: Dosage forms of fosfomycin-Ca salt, capsule and granules, were prepared for its clinical trials. It resulted effective in about 76% of 1,200 patients with infection due to gram-positive or gram-negative (Pseudomonas, Salmonella, Escherichia coli, etc.) bacteria in several fields. As far as rates of efficacy were concerned, it was more effective in surgical, urological, ophthalmic and some other fields than in internal and pediatric ones. Fosfomycin was given in a dose of 2-3 g/day for adults or 100-130 mg/kg for infants and children in most cases. Furthermore, it can be favorably mentioned that fosfomycin was proved to be effective in salmonellosis and resistant shigellosis by a certain research group specialized in the therapy of infectious enteritis. Clinical results of its parenteral form: Sterlized bulk material of fosfomycin-Na salt was prepared in a vial for clinical use. Similarly as in the case of oral form, it was applied to about 500 patients with several infections. It resulted effective in about 68% of them. This percentage was not as high because of the higher frequency of application to severe patients or patients with underlying disease. Fosfomycin was intravenously administered by one shot or drip infusion in a dose of 2-4 g/day for adults, or 100-250 mg/kg for infants and children in most cases. Adverse reactions: In oral form, the incidence of adverse reactions was about 10% but most of them were slight gastrointestinal disorders. In an extremely small number of patients a rise of SGOT and/or SGPT was observed. In parenteral form, the incidence of adverse reactions was a little higher, being about 17% including a rise of SGOT and/or SGPT, vascular pain, nausea, and vomiting, etc...

Administration, Oral↗
PubMed1977

Carcino-fetal proteins and gastric cancer: the site of alpha-fetoprotein synthesis in gastric cancer.

Although several investigators have reported serum alpha-fetoprotein positive gastric cancer with or without metastasis to the liver, its site of production is still unclear. We studied on the site of alpha-fetoprotein synthesis in our cases which showed remarkably high level of serum alpha-fetoprotein, and clarified the presence of alpha-fetoprotein producing gastric cancer by means of direct immunofluorescent technique. However, we also knew the hepatocytes adjacent ot the metastatic lesions could also synthesize alpha-fetoprotein, although these hepatocytes were not known whether under regeneration or degeneration. Through this study, the other carcinofetal proteins such as carcino-placental alkaline phosphatase and CEA were examined using the sera or tumor tissues. Our results will support the idea that cancer is the disease of cell differentiation.

Adenocarcinoma↗